VAP Incidence and Adequation to SRLF 2017 Diagnostic Among an Intensive Care Medicine Service for the Period 2022 à 2024

Not yet recruiting

• Conditions: Pneumonia Ventilator Associated

• Registration Number: NCT07181824
• Lead Sponsor: Centre Hospitalier Sud Francilien

Brief Summary

The goal of this observational study is to to analyze respiratory samples performed in mechanically ventilated ICU patients and to assess whether the SRLF criteria for defining VAP were respected among patients admited to the Intensive care medicine at a regional hospital en France

Detailed Description

Ventilator-associated pneumonia (VAP) is a lung infection that occurs after more than 48 hours of mechanical ventilation. It is of particular interest because it affects between 5-40% of ICU patients depending on the study and diagnostic criteria, with a relatively low attributable mortality (around 10%), but with increased morbidity, notably in terms of the duration of mechanical ventilation and ICU length of stay. In addition, it is the leading cause of nosocomial infection in the ICU, accounting for up to 25% of antibiotic use for hospital-acquired infections.

The diagnosis of VAP is based on clinico-radiological criteria: the appearance or worsening of a radiological pulmonary infiltrate, an inflammatory syndrome, the appearance of secretions, increased oxygen dependency and/or worsening of shock, confirmed by a positive respiratory sample.

The diagnostic challenge lies in the fact that the signs and symptoms are not pathognomonic of VAP and may be common to other conditions. On the other hand, patients may be colonized by pathogens without actually having VAP.

For this reason, scientific societies propose criteria to better target patients for whom a respiratory sample should be taken and antibiotic therapy initiated.

In 2017, the French Society of Intensive Care Medicine (SRLF) and the French Society of Anaesthesia and Intensive Care (SFAR) published recommendations on ICU-associated pneumonia, with some minor variations compared with the 2005 ATS/IDSA criteria.

Our study aims to analyze respiratory samples performed in mechanically ventilated ICU patients and to assess whether the SRLF criteria for defining VAP were respected.

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-12
• Study First Submitted QC: 2025-09-12
• Last Update Submitted: 2025-09-12
• Study First Posted: 2025-09-18
• Last Update Posted: 2025-09-18
• Study Start: 2025-09-24
• Primary Completion: 2025-10-30
• Study Completion: 2025-10-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Adults ≥ 18 years
• Hospitalization in Intensive care unit for the period between 01/01/2022 and 31/12/2024
• Intubation and mechanical ventilation for > 48h
• Positive respiratory sample

Exclusion Criteria

• Decision of therapeutic limitation
• Organ donors
• Patient refuse to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SRLF VAP criteria	at day 0	Describe whether the respiratory samples obtained from ICU patients after \>48 hours of mechanical ventilation for suspected VAP met, or did not meet, the 2017 SRLF diagnostic criteria

Secondary Outcome Measures

Name	Time	Method
microbial ecology in the ICU of CHSF	at day 0	Prevalence of MDR in the respiratory samples
antibiotic consumption generated by VAP	at day 0	To evaluate antibiotic consuming related to VAP episodes to the total antibiotic consuming in the Intensive care unit
morbidity and mortality associated with VAP	at day 0	Mortality and mechanical ventilation duration among patients diagnosed of VAP
duration of antibiotic therapy for a VAP episode	at day 0	Duration of antibiotherapy among patients with VAP
characteristics of the initial antibiotic therapy	at day 0	Number and class of antibiotics of the initial antibiotic therapy
Evaluate the adequacy of the initial antibiotic therapy	at day 0	Adequation of the initial therapy compared to the definitive therapy: maintain, increase or reduce the spectrum or number of antibiotics

Trial Locations

Locations (1)

Centre Hospitalier Sud Francilien; 🇫🇷 Corbeil-Essonnes, France, France